CYP2A6, MAOA, DBH, DRD4, and 5HT2A genotypes, smoking behaviour and cotinine levels in 1518 UK adolescents

Pharmacogenetics and Genomics

Volumn 15, Issue 12, 2005, Pages 839-850

  Huang, Shuwen ^a   Cook, Derek G ^b   Hinks, Lesley J ^a   Chen, Xiao He ^a   Ye, Shu ^a   Gilg, Julie A ^b   Jarvis, Martin J ^c   Whincup, Peter H ^b   Day, Ian N M ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

5HT2A; CYP2A6; DBH; DRD4; Haploinsufficiency; MAOA; Nicotine metabolism; Nicotine occupancy; Smoking behaviour

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; COTININE; CYTOCHROME P450 2A6; DOPAMINE BETA MONOOXYGENASE; DOPAMINE RECEPTOR; NICOTINE; SEROTONIN 2 RECEPTOR;

ADOLESCENT; ADULT; ALLELE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENOTYPE; HOMOZYGOTE; HUMAN; MALE; METABOLIC RATE; PREDICTION; PRIORITY JOURNAL; QUESTIONNAIRE; RISK ASSESSMENT; SALIVA ANALYSIS; SMOKING;

EID: 27944456075     PISSN: 17446872     EISSN: None     Source Type: Journal    
DOI: 10.1097/01213011-200512000-00002     Document Type: Article

References (53)

1. Blenkinsop SSS. Chapter 9: Smoking. In: Boreham RSA (editor): Drug use smoking and drinking among young people in England in 2001. London: The Stationary Office; 2002, pp. 171-177.
2. Hall W, Madden P, Lynskey M. The genetics of tobacco use: methods, findings and policy implications. Tob Control 2002; 11:119-124.
3. Nakajima M, Kwon JT, Tanaka N, Zenta T, Yamamoto Y, Yamamoto H, et al. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. Clin Pharmacol Ther 2001; 69:72-78.
4. Kwon JT, Nakajima M, Chai S, Yom YK, Kim HK, Yamazaki H, et al. Nicotine metabolism and CYP2A6 allele frequencies in Koreans. Pharmacogenetics 2001; 11:317-323.
5. Ujjin P, Satarug S, Vanavanitkun Y, Daigo S, Ariyoshi N, Yamazaki H, et al. Variation in coumarin 7-hydroxylase activity associated with genetic polymorphism of cytochrome P450 2A6 and the body status of iron stores in adult Thai males and females. Pharmacogenetics 2002; 12:241-249.
6. Vasconcelos GM, Struchiner CJ, Suarez-Kurtz G. CYP2A6 genetic polymorphisms and correlation with smoking status in Brazilians. Pharmacogenomics J 2005; 5:42-48.
7. Gambier N, Batt AM, Marie B, Pfister M, Siest G, Visvikis-Siest S. Association of CYP2A6*1B genetic variant with the amount of smoking in French adults from the Stanislas cohort. Pharmacogenomics J 2005; 5:271-275.
8. Rao Y, Hoffmann E, Zia M, Bodin L, Zeman M, Sellers EM, et al. Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol Pharmacol 2000; 58:747-755.
9. Tyndale RF, Sellers EM. Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk. Drug Metab Dispos 2001; 29:548-552.
10. Schoedel KA, Hoffmann EB, Rao Y, Sellers EM, Tyndale RF. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 2004; 14:615-626.
11. Gu DF, Hinks LJ, Morton NE, Day IN. The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit. Ann Hum Genet 2000; 64:383-390.
12. London SJ, Idle JR, Daly AK, Coetzee GA. Genetic variation of CYP2A6, smoking, and risk of cancer. Lancet 1999; 353:898-899.
13. Schulz TG, Ruhnau P, Hallier E. Lack of correlation between CYP2A6 genotype and smoking habits. Adv Exp Med Biol 2001; 500:213-215.
14. Loriot MA, Rebuissou S, Oscarson M, Cenee S, Miyamoto M, Ariyoshi N, et al. Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population. Pharmacogenetics 2001; 11:39-44.
15. Tan W, Chen GF, Xing DY, Song CY, Kadlubar FF, Lin DX. Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population. Int J Cancer 2001; 95:96-101.
16. Tiihonen J, Pesonen U, Kauhanen J, Koulu M, Hallikainen T, Leskinen L, et al. CYP2A6 genotype and smoking. Mol Psychiatry 2000; 5:347-348.
17. Zhang X, Amemo K, Ameno S, Iwahashi K, Kinoshita H, Kubota T, et al. Lack of association between smoking and CYP2A6 gene polymorphisms in a Japanese population. Nihon Arukoru Yakubutsu Igakkai Zasshi 2001; 36:486-490.
18. O'Loughlin J, Paradis G, Kim W, DiFranza J, Meshefedjian G, McMillan-Davey E, et al. Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers. Tob Control 2004; 13:422-428.
19. McKinney EF, Walton RT, Yudkin P, Fuller A, Haldar NA, Mant D, et al. Association between polymorphisms in dopamine metabolic enzymes and tobacco consumption in smokers. Pharmacogenetics 2000; 10:483-491.
20. Sabol SZ, Hu S, Hamer D. A functional polymorphism in the monoamine oxidase A gene promoter. Hum Genet 1998; 103:273-279.
21. Ito H, Hamajima N, Matsuo K, Okuma K, Sato S, Ueda R, et al. Monoamine oxidase polymorphisms and smoking behaviour in Japanese. Pharmacogenetics 2003; 13:73-79.
22. Ebstein RP, Novick O, Umansky R, Priel B, Osher Y, Blaine D, et al. Dopamine D4 receptor (D4DR) exon III polymorphism associated with the human personality trait of Novelty Seeking. Nat Genet 1996; 12:78-80.
23. Vandenbergh DJ, Rodriguez LA, Hivert E, Schiller JH, Villareal G, Pugh EW, et al. Long forms of the dopamine receptor (DRD4) gene VNTR are more prevalent in substance abusers: no interaction with functional alleles of the catechol-o-methyltransferase (COMT) gene. Am J Med Genet 2000; 96:678-683.
24. Hutchison KE, McGeary J, Smolen A, Bryan A, Swift RM. The DRD4 VNTR polymorphism moderates craving after alcohol consumption. Health Psychol 2002; 21:139-146.
25. Hutchison KE, LaChance H, Niaura R, Bryan A, Smolen A. The DRD4 VNTR polymorphism influences reactivity to smoking cues. J Abnorm Psychol 2002; 111:134-143.
26. Shields PG, Lerman C, Audrain J, Bowman ED, Main D, Boyd NR, et al. Dopamine D4 receptors and the risk of cigarette smoking in African-Americans and Caucasians. Cancer Epidemiol Biomarkers Prev 1998; 7:453-458.
27. do Prado-Lima PA, Chatkin JM, Taufer M, Oliveira G, Silveira E, Neto CA, et al. Polymorphism of 5HT2A serotonin receptor gene is implicated in smoking addiction. Am J Med Genet 2004; 128B:90-93.
28. Luciano M, Zhu G, Kirk KM, Whitfield JB, Butler R, Heath AC, et al. Effects of dopamine receptor D4 variation on alcohol and tobacco use and on novelty seeking: multivariate linkage and association analysis. Am J Med Genet 2004; 124B:113-123.
29. Terayama H, Itoh M, Fukunishi I, Iwahashi K. The serotonin-2A receptor polymorphism and smoking behavior in Japan. Psychiatr Genet 2004; 14:195-197.
30. Whincup PH, Cook DG, Adshead F, Taylor S, Papacosta O, Walker M, et al. Cardiovascular risk factors in British children from towns with widely differing adult cardiovascular mortality. BMJ 1996; 313:79-84.
31. Whincup PH, Gilg JA, Papacosta O, Seymour C, Miller GJ, Alberti KG, et al. Early evidence of ethnic differences in cardiovascular risk: cross sectional comparison of British South Asian and white children. BMJ 2002; 324:635.
32. Feyerabend C, Russell MA. A rapid gas-liquid chromatographic method for the determination of cotinine and nicotine in biological fluids. J Pharm Pharmacol 1990; 42:450-452.
33. Jarvis L. Smoking among secondary school children in 1996: England, 1997. London: The Stationery Office; 1997.
34. McNeill AD, Jarvis MJ, West R, Russell MA, Bryant A. Saliva cotinine as an indicator of cigarette smoking in adolescents. Br J Addict 1987; 82:1355-1360.
35. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16:1215.
36. Fernandez-Salguero P, Hoffman SM, Cholerton S, Mohrenweiser H, Raunio H, Rautio A, et al. A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am J Hum Genet 1995; 57:651-660.
37. Lichter JB, Barr CL, Kennedy JL, Van Tol HH, Kidd KK, Livak KJ. A hypervariable segment in the human dopamine receptor D4 (DRD4) gene. Hum Mol Genet 1993; 2:767-773.
38. Oscarson M, Gullsten H, Rautio A, Bernal ML, Sinues B, Dahl ML, et al. Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. FEBS Lett 1998; 438:201-205.
39. Oscarson M, McLellan RA, Gullsten H, Yue QY, Lang MA, Bernal ML, et al. Characterization and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett 1999; 448:105-110.
40. Oscarson M, McLellan RA, Gullsten H, Agundez JA, Benitez J, Rautio A et al. Identification and characterization of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. FEBS Lett 1999; 460:321-327.
41. Oscarson M, McLellan RA, Asp V, Ledesma M, Ruiz ML, Sinues B, et al. Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity. Hum Mutat 2002; 20:275-283.
42. Day IN, Humphries SE. Electrophoresis for genotyping: microtiter array diagonal gel electrophoresis on horizontal polyacrylamide gels, hydrolink, or agarose. Anal Biochem 1994; 222:389-395.
43. O'Dell SD, Gaunt TR, Day IN. SNP genotyping by combination of 192-well MADGE, ARMS and computerized gel image analysis. Biotechniques 2000; 29:500-506.
44. Ye S, Dhillon S, Ke X, Collins AR, Day IN. An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res 2001; 29:E88.
45. Chen XH, O'Dell SD, Day IN. Microplate array diagonal gel electrophoresis for cohort studies of microsatellite loci. Biotechniques 2002; 32:1080-1082, 1084, 1086.
46. Marshall SE, Bird TG, Hart K, Welsh KI. Unified approach to the analysis of genetic variation in serotonergic pathways. Am J Med Genet 1999; 88:621-627.
47. Todd RD, Neuman RJ, Lobos EA, Jong YJ, Reich W, Heath AC. Lack of association of dopamine D4 receptor gene polymorphisms with ADHD subtypes in a population sample of twins. Am J Med Genet 2001; 105:432-438.
48. Xu C, Goodz S, Sellers EM, Tyndale RF. CYP2A6 genetic variation and potential consequences. Adv Drug Deliv Rev 2002; 54:1245-1256.
49. Yamanaka H, Nakajima M, Nishimura K, Yoshida R, Fukami T, Katoh M, et al. Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted. Eur J Pharm Sci 2004; 22:419-425.
50. Benowitz NL, Pomerleau OF, Pomerleau CS, Jacob P, III. Nicotine metabolite ratio as a predictor of cigarette consumption. Nicotine Tob Res 2003; 5:621-624.
51. Yoshida R, Nakajima M, Nishimura K, Tokudome S, Kwon JT, Yokoi T. Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. Clin Pharmacol Ther 2003; 74:69-76.
52. Pitarque M, von Richter O, Oke B, Berkkan H, Oscarson M, Ingelman-Sundberg M. Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. Biochem Biophys Res Commun 2001; 284:455-460.
53. Edwards R. The problem of tobacco smoking. BMJ 2004; 328:217-219.